finanznachrichten.de
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026
This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.
Patients and clinicians tracking new therapies or complications like intestinal fibrosis may find the upcoming ECCO presentations relevant.
Clinicians and researchers in IBD, adult patients and caregivers following investigational IBD therapies, and patients concerned about fibrosis/stricture complications.
What To Know
Abivax will present 22 abstracts on obefazimod at ECCO 2026, including an oral talk reporting preclinical anti-fibrotic activity and multiple analyses from Phase 3 ABTECT induction trials in ulcerative colitis.
The abstracts cover efficacy, safety, cytokine/biomarker changes, subgroup analyses, and a preclinical fibrosis study relevant to Crohn’s-related strictures. The company is sharing expanded clinical and preclinical data for obefazimod — an investigational therapy — at a major IBD conference.
The oral presentation highlights preclinical anti-fibrotic findings (in cell and mouse models) and the rest of the abstracts include pooled Phase 3 trial data (ABTECT-1/2) on symptoms, biomarkers, and tolerability in ulcerative colitis.
These presentations describe research findings and help the scientific community evaluate obefazimod’s potential, but they do not by themselves change clinical care. If you follow IBD research or clinical trials, these abstracts are a source of new data to watch as peer-reviewed publication or regulatory updates follow.
For more detail, see the company’s ECCO 2026 program listings and the original Abivax announcement for the full abstract titles and presenters.
These are conference abstract presentations and preclinical/model findings; they are not definitive clinical evidence or regulatory decisions. Phase 3 trial subgroup analyses and preclinical anti-fibrotic results require peer review and replication before changing practice. The source is a company press release summarizing its ECCO abstracts.
